AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15111779 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation (Control)
Number of subjects: 79
Study 15111779 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study 15111779 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly group
Number of subjects: 79
Study 15111779 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and control groups
Number of subjects: 79
Study 11157138 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (15 days i.v. followed by 21 days oral)
Number of subjects: 75
Study 11157138 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of leg ulcers
Number of subjects: 75
Study 11157138 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised white cell count (WCC) at presentation
Number of subjects: 75
Study 11157138 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of abnormal renal function
Number of subjects: 75
Study 9626844 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy with nitrates and atenolol or verapamil
Number of subjects: 70
Study 9626844 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated patients)
Number of subjects: 70
Study 9626844 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 70
Study 7936821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum inoculation
Number of subjects: 31
Study 7936821 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk containing B. bifidum growth-promoting factor
Number of subjects: 31
Study 7936821 — intervention group
Group type: COMPARATOR
Intervention: Formula milk without B. bifidum growth-promoting factor
Number of subjects: 31
Study 3215887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 7
Study 3215887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31453877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 313
Study 31453877 — intervention group
Group type: COMPARATOR
Intervention: Volatile inhalational agents (desflurane or sevoflurane)
Number of subjects: 313
Study 31547446 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the RDA (2RDA: 1.6 g protein/kg bodyweight/day)
Number of subjects: 29
Study 31547446 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the RDA (2RDA)
Number of subjects: 29
Study 31547446 — intervention group
Group type: COMPARATOR
Intervention: Recommended dietary allowance (RDA: 0.8 g protein/kg bodyweight/day)
Number of subjects: 29
Study 28544241 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 IU of RRR‐alpha‐tocopherol
Number of subjects: 50
Study 28544241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 50
Study 28544241 — intervention group
Group type: COMPARATOR
Intervention: Comparison of serum levels between treatment and control groups
Number of subjects: 50
Study 26892694 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 155
Study 26892694 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 155
Study 23899829 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training-placebo (AT-PLA)
Number of subjects: 45
Study 23899829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training-estrogen therapy (AT-ET)
Number of subjects: 45
Study 23899829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary-estrogen therapy (SED-ET)
Number of subjects: 45
Study 23899829 — intervention group
Group type: COMPARATOR
Intervention: Sedentary-placebo (SED-PLA)
Number of subjects: 45
Study 21853229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA) 4 mg
Number of subjects: 20
Study 21853229 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 20
Study 21853229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IVTA and PPV
Number of subjects: 20
Study 19651674 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (9 g/day)
Number of subjects: 26
Study 19651674 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (21 g/day)
Number of subjects: 26
Study 19651674 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine plus creatine
Number of subjects: 26
Study 19651674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17301040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent nonpharmacological intervention (increased exposure to outdoor bright light, structured physical activity, bedtime routine, reduced nighttime noise and light)
Number of subjects: 100
Study 17301040 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 100
Study 15133346 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasonography (EBUS)
Number of subjects: 50
Study 15133346 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy only (Control)
Number of subjects: 50
Study 11590377 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once daily)
Number of subjects: 25
Study 11590377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10211537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg on day 1, then 200 mg once daily for 9 days)
Number of subjects: 504
Study 10211537 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice daily for 14 days)
Number of subjects: 504
Study 10211537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 504
Study 10211537 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 504
Study 8545871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (NL)
Number of subjects: 9
Study 8545871 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (SM)
Number of subjects: 9
Study 2205289 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly
Number of subjects: 19
Study 2205289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 310164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 90
Study 310164 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 90
Study 310164 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate with concomitant trisulfapyrimidines
Number of subjects: 90
Study 31221208 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) intervention with age-appropriate procedural information.
Number of subjects: 200
Study 31221208 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group).
Number of subjects: 200
Study 31221208 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) intervention.
Number of subjects: 200
Study 29173736 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 29173736 — intervention group
Group type: COMPARATOR
Intervention: Stimulant plus Parent Training (PT)
Number of subjects: 0
Study 26001318 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion at nil μg kg(‐1) min(‐1)
Number of subjects: 108
Study 26001318 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.05 μg kg(‐1) min(‐1)
Number of subjects: 108
Study 26001318 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.10 μg kg(‐1) min(‐1)
Number of subjects: 108
Study 26001318 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.15 μg kg(‐1) min(‐1)
Number of subjects: 108
Study 26001318 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.20 μg kg(‐1) min(‐1)
Number of subjects: 108
Study 26001318 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.25 μg kg(‐1) min(‐1)
Number of subjects: 108
Study 23379836 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold 8-mm-tip ablation
Number of subjects: 428
Study 23379836 — intervention group
Group type: COMPARATOR
Intervention: Platinum-iridium 8-mm-tip ablation
Number of subjects: 428
Study 21723781 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-pleural pneumonectomy (EPP)
Number of subjects: 50
Study 21723781 — intervention group
Group type: COMPARATOR
Intervention: No extra-pleural pneumonectomy (no EPP)
Number of subjects: 50
Study 19010636 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cc fibrin glue after RILND
Number of subjects: 58
Study 19010636 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9 percent irrigation
Number of subjects: 58
Study 17523990 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback (PF)
Number of subjects: 188
Study 17523990 — intervention group
Group type: COMPARATOR
Intervention: Multi-media Feedback (MMF)
Number of subjects: 188
Study 17523990 — intervention group
Group type: COMPARATOR
Intervention: Delayed Feedback Control (DFC)
Number of subjects: 188
Study 14747423 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (high-tissue-penetrating ACE inhibitor)
Number of subjects: 30
Study 14747423 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (low-tissue-penetrating ACE inhibitor)
Number of subjects: 30
Study 11392657 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular rehabilitation with supported treadmill ambulation training (STAT)
Number of subjects: 12
Study 11392657 — intervention group
Group type: COMPARATOR
Intervention: Regular rehabilitation (REG)
Number of subjects: 12
Study 9717012 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (bicycle training at 80% of maximal intensity for 4 months)
Number of subjects: 54
Study 9717012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 7946861 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 20
Study 7946861 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anaesthesia
Number of subjects: 20
Study 1842749 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol, 50 mg three times a day
Number of subjects: 39
Study 342626 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus bivalent influenza vaccine
Number of subjects: 0
Study 342626 — intervention group
Group type: COMPARATOR
Intervention: Ether-split bivalent influenza vaccine
Number of subjects: 0
Study 342626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass influenza vaccination program
Number of subjects: 0
Study 30907881 — intervention group
Group type: EXPERIMENTAL
Intervention: Video demonstration on PA intensity levels
Number of subjects: 0
Study 30907881 — intervention group
Group type: COMPARATOR
Intervention: Control group (PA assessment only)
Number of subjects: 0
Study 27883203 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implant-abutment connection
Number of subjects: 80
Study 27883203 — intervention group
Group type: COMPARATOR
Intervention: Conventional platform-matched implant-abutment connection
Number of subjects: 80
Study 27883203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 80
Study 26032852 — intervention group
Group type: EXPERIMENTAL
Intervention: PLISSIT model intervention (sexual counselling from general practitioner)
Number of subjects: 0
Study 26032852 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23681934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 352
Study 23681934 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 352
Study 16787931 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Regional Analgesia (PCRA) with ropivacaine 0.2%
Number of subjects: 30
Study 16787931 — intervention group
Group type: COMPARATOR
Intervention: Continuous Regional Analgesia (CRA) with ropivacaine 0.2%
Number of subjects: 30
Study 16787931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCRA and CRA
Number of subjects: 30
Study 15195074 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan (BU) 150 mg/m2 given as four single daily doses
Number of subjects: 63
Study 15195074 — intervention group
Group type: COMPARATOR
Intervention: Busulphan (BU) 4 mg/kg given as four single daily doses
Number of subjects: 63
Study 10367611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive medication
Number of subjects: 54
Study 10367611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8889266 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg
Number of subjects: 15
Study 8889266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 15
Study 8889266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg
Number of subjects: 15
Study 8889266 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 15
Study 8889266 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 15
Study 8889266 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 15
Study 8889266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1323811 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide/Cisplatin (EP)
Number of subjects: 0
Study 1323811 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/Carboplatin
Number of subjects: 0
Study 1323811 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Cisplatin/Etoposide with concurrent thoracic irradiation
Number of subjects: 0
Study 1323811 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum/Etoposide
Number of subjects: 0
Study 1323811 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 6507909 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride (5 mg/ml)
Number of subjects: 12
Study 6507909 — intervention group
Group type: COMPARATOR
Intervention: Midazolam maleate (2.5 mg/ml)
Number of subjects: 12
Study 31326680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lead handheld ECG screening for AF
Number of subjects: 16000
Study 31326680 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16000
Study 28899524 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) adherence for six months
Number of subjects: 0
Study 25349333 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 5794
Study 25349333 — intervention group
Group type: COMPARATOR
Intervention: High CRP (>3 mg/L)
Number of subjects: 5794
Study 23786930 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC+M (salmeterol/futicasone plus montelukast)
Number of subjects: 38
Study 23786930 — intervention group
Group type: COMPARATOR
Intervention: SFC (salmeterol/futicasone plus placebo)
Number of subjects: 38
Study 23786930 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC+M
Number of subjects: 38
Study 23786930 — intervention group
Group type: COMPARATOR
Intervention: SFC
Number of subjects: 38
Study 21784046 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (24-72 weeks)
Number of subjects: 398
Study 21784046 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (48 weeks)
Number of subjects: 398
Study 21784046 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (24-30 weeks) for rapid responders
Number of subjects: 398
Study 21784046 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment (60-72 weeks) for slow responders
Number of subjects: 398
Study 19804620 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS)
Number of subjects: 480
Study 19804620 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Lasting Insecticide Treated Nets (LLIN)
Number of subjects: 480
Study 19804620 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Management (EVM) - Mud Plastering
Number of subjects: 480
Study 19804620 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Management (EVM) - Lime Plastering
Number of subjects: 480
Study 19804620 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 480
Study 17177749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment with retinyl-based cream
Number of subjects: 20
Study 17177749 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) treatment only
Number of subjects: 20
Study 13679494 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 48
Study 13679494 — intervention group
Group type: COMPARATOR
Intervention: Tertatolol (5-10 mg/day)
Number of subjects: 48
Study 11003207 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported alcohol consumption
Number of subjects: 209
Study 8638692 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 15
Study 8638692 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhGH treatment)
Number of subjects: 15
Study 1420750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (500 mg)
Number of subjects: 16
Study 1420750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (1.8 mg/kg)
Number of subjects: 16
Study 1420750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (500 mg) b.d.
Number of subjects: 16
Study 1420750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3973067 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 43
Study 3973067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3973067 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial treatment
Number of subjects: 43
Study 30381138 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 10 mg
Number of subjects: 220
Study 30381138 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 220
Study 30381138 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 220
Study 30381138 — intervention group
Group type: COMPARATOR
Intervention: Control regimen of ondansetron
Number of subjects: 220
Study 29894717 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated/customized text messages and phone calls, followed by text message reminders
Number of subjects: 1220
Study 29894717 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (written letter)
Number of subjects: 1220
Study 29894717 — intervention group
Group type: COMPARATOR
Intervention: Text messages and reminders only
Number of subjects: 1220
Study 27019280 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK)
Number of subjects: 208
Study 27019280 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX
Number of subjects: 208
Study 27019280 — intervention group
Group type: EXPERIMENTAL
Intervention: OVK and SPARX combined
Number of subjects: 208
Study 27019280 — intervention group
Group type: COMPARATOR
Intervention: Monitoring control condition
Number of subjects: 208
Study 25087837 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + interactive videogame-aided exercises (EG)
Number of subjects: 40
Study 25087837 — intervention group
Group type: COMPARATOR
Intervention: Standard PRP (CG)
Number of subjects: 40
Study 22420526 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days
Number of subjects: 474
Study 22420526 — intervention group
Group type: COMPARATOR
Intervention: Vehicle administered twice daily for 3 days
Number of subjects: 474
Study 20137091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist Care Group (PCG)
Number of subjects: 546
Study 20137091 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 546
Study 20137091 — intervention group
Group type: COMPARATOR
Intervention: Hidden Control Group (HCG)
Number of subjects: 546
Study 17432674 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Powder (DXP)
Number of subjects: 63
Study 17432674 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (Control)
Number of subjects: 63
Study 16781589 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel S ointment
Number of subjects: 357
Study 16781589 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 1% gel
Number of subjects: 357
Study 16781589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 357
Study 11871813 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue applied onto the surface of the leaking raw lung (Group A)
Number of subjects: 30
Study 11871813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled pericardial fat pad fixed with fibrin glue (Group B)
Number of subjects: 30
Study 10429002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral ventriculomegaly (VM) at term
Number of subjects: 257
Study 10429002 — intervention group
Group type: COMPARATOR
Intervention: No cerebral ventriculomegaly (VM)
Number of subjects: 257
Study 7742723 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg) daily for 6 months
Number of subjects: 331
Study 7742723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar-appearing) daily for 6 months
Number of subjects: 331
Study 7742723 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg)
Number of subjects: 331
Study 7742723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 2201724 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (TRZ, 0.25 mg)
Number of subjects: 12
Study 2201724 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (ZOP, 7.5 mg)
Number of subjects: 12
Study 2201724 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 12
Study 2201724 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (TRZ, 0.25 mg) + Alcohol (0.8 g/kg)
Number of subjects: 12
Study 2201724 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone (ZOP, 7.5 mg) + Alcohol (0.8 g/kg)
Number of subjects: 12
Study 7018605 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation
Number of subjects: 0
Study 7018605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative formulation
Number of subjects: 0